Skip to main content
Erschienen in: Clinical and Experimental Medicine 1/2017

29.10.2015 | Original Article

Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7

verfasst von: Yongzheng Bao, Bin Chen, Qiang Wu, Konghe Hu, Xinhua Xi, Wengang Zhu, Xueren Zhong, Jianting Chen

Erschienen in: Clinical and Experimental Medicine | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Osteosarcoma (OS) is one of the most common types of primary sarcoma of bone in children and young adults, and the long-term prognosis for OS patients still remains dismal due to the lack of effective early diagnostic biomarkers. Identifying sensitive and specific biomarkers in carcinogenesis may improve diagnostic and therapeutic strategies for this malignancy. The expression of miR-664 in osteosarcoma cell lines and osteosarcoma tissues was examined using real-time PCR. The effects of miR-664 on osteosarcoma cell migration and invasion were evaluated by cell invasion assays, migration assays, and three-dimension spheroid invasion assay. The effect of miR-664 on SOX7 was determined by luciferase assays and Western blot assay. The clinical association between miR-664 and SOX7 was analyzed by real-time PCR and Western blot assay. Expression of miR-664 was found to be upregulated in OS cell lines and tissues. Overexpression of miR-664 was associated with increased migration and invasive abilities of OS cells in vitro, whereas downregulation of miR-664 appeared to inhibit their migration and invasive potential. Furthermore, using biological approaches, we showed that miR-664 directly targeted and suppressed expression of the tumor suppressor SOX7. Additionally, the expression of miR-664 was negatively correlated with SOX7 expression in OS clinical tissues. Our findings suggest that miR-664 functions as an oncogene miRNA and has an important role in promoting human OS cell invasion and migration by suppressing SOX7 expression. Consequently, miR-664 may have potential as a novel diagnostic and therapeutic target of osteosarcoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ando K, Heymann MF, Stresing V, Mori K, Redini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers. 2013;5:591–616.CrossRefPubMedPubMedCentral Ando K, Heymann MF, Stresing V, Mori K, Redini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers. 2013;5:591–616.CrossRefPubMedPubMedCentral
3.
4.
Zurück zum Zitat Messerschmitt PJ, Rettew AN, Brookover RE, Garcia RM, Getty PJ, Greenfield EM. Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res. 2008;466:2168–75.CrossRefPubMedPubMedCentral Messerschmitt PJ, Rettew AN, Brookover RE, Garcia RM, Getty PJ, Greenfield EM. Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res. 2008;466:2168–75.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422–41.CrossRefPubMed Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422–41.CrossRefPubMed
6.
Zurück zum Zitat Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol. 1994;12:2614–20.PubMed Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol. 1994;12:2614–20.PubMed
7.
Zurück zum Zitat Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMed Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMed
8.
Zurück zum Zitat Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis. 2007;28:2–12.CrossRefPubMed Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis. 2007;28:2–12.CrossRefPubMed
9.
10.
11.
Zurück zum Zitat Xu JQ, Liu P, Si MJ, Ding XY. MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1. Tumour Biol. 2013;34:3871–7.CrossRefPubMed Xu JQ, Liu P, Si MJ, Ding XY. MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1. Tumour Biol. 2013;34:3871–7.CrossRefPubMed
12.
Zurück zum Zitat Xu Z, Wang T. miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1. Biochem Biophys Res Commun. 2014;449:190–5.CrossRefPubMed Xu Z, Wang T. miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1. Biochem Biophys Res Commun. 2014;449:190–5.CrossRefPubMed
13.
Zurück zum Zitat Kelly AD, Haibe-Kains B, Janeway KA, Hill KE, Howe E, Goldsmith J, Kurek K, Perez-Atayde AR, Francoeur N, Fan JB, April C, Schneider H, Gebhardt MC, Culhane A, Quackenbush J, Spentzos D. MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. Genome Med. 2013;5:2.CrossRefPubMedPubMedCentral Kelly AD, Haibe-Kains B, Janeway KA, Hill KE, Howe E, Goldsmith J, Kurek K, Perez-Atayde AR, Francoeur N, Fan JB, April C, Schneider H, Gebhardt MC, Culhane A, Quackenbush J, Spentzos D. MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. Genome Med. 2013;5:2.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol. 2000;227:239–55.CrossRefPubMed Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol. 2000;227:239–55.CrossRefPubMed
15.
Zurück zum Zitat Gandillet A, Serrano AG, Pearson S, Lie ALM, Lacaud G, Kouskoff V. Sox7-sustained expression alters the balance between proliferation and differentiation of hematopoietic progenitors at the onset of blood specification. Blood. 2009;114:4813–22.CrossRefPubMed Gandillet A, Serrano AG, Pearson S, Lie ALM, Lacaud G, Kouskoff V. Sox7-sustained expression alters the balance between proliferation and differentiation of hematopoietic progenitors at the onset of blood specification. Blood. 2009;114:4813–22.CrossRefPubMed
16.
Zurück zum Zitat Cermenati S, Moleri S, Cimbro S, Corti P, Del Giacco L, Amodeo R, Dejana E, Koopman P, Cotelli F, Beltrame M. Sox18 and Sox7 play redundant roles in vascular development. Blood. 2008;111:2657–66.CrossRefPubMed Cermenati S, Moleri S, Cimbro S, Corti P, Del Giacco L, Amodeo R, Dejana E, Koopman P, Cotelli F, Beltrame M. Sox18 and Sox7 play redundant roles in vascular development. Blood. 2008;111:2657–66.CrossRefPubMed
17.
Zurück zum Zitat Francois M, Koopman P, Beltrame M. SoxF genes: key players in the development of the cardio-vascular system. Int J Biochem Cell Biol. 2010;42:445–8.CrossRefPubMed Francois M, Koopman P, Beltrame M. SoxF genes: key players in the development of the cardio-vascular system. Int J Biochem Cell Biol. 2010;42:445–8.CrossRefPubMed
18.
Zurück zum Zitat Seguin CA, Draper JS, Nagy A, Rossant J. Establishment of endoderm progenitors by SOX transcription factor expression in human embryonic stem cells. Cell Stem Cell. 2008;3:182–95.CrossRefPubMed Seguin CA, Draper JS, Nagy A, Rossant J. Establishment of endoderm progenitors by SOX transcription factor expression in human embryonic stem cells. Cell Stem Cell. 2008;3:182–95.CrossRefPubMed
19.
Zurück zum Zitat Zhang Y, Huang S, Dong W, Li L, Feng Y, Pan L, Han Z, Wang X, Ren G, Su D, Huang B, Lu J. SOX7, down-regulated in colorectal cancer, induces apoptosis and inhibits proliferation of colorectal cancer cells. Cancer Lett. 2009;277:29–37.CrossRefPubMed Zhang Y, Huang S, Dong W, Li L, Feng Y, Pan L, Han Z, Wang X, Ren G, Su D, Huang B, Lu J. SOX7, down-regulated in colorectal cancer, induces apoptosis and inhibits proliferation of colorectal cancer cells. Cancer Lett. 2009;277:29–37.CrossRefPubMed
20.
Zurück zum Zitat Stovall DB, Wan M, Miller LD, Cao P, Maglic D, Zhang Q, Stampfer MR, Liu W, Xu J, Sui G. The regulation of SOX7 and its tumor suppressive role in breast cancer. Am J Pathol. 2013;183:1645–53.CrossRefPubMedPubMedCentral Stovall DB, Wan M, Miller LD, Cao P, Maglic D, Zhang Q, Stampfer MR, Liu W, Xu J, Sui G. The regulation of SOX7 and its tumor suppressive role in breast cancer. Am J Pathol. 2013;183:1645–53.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Katoh M. Expression of human SOX7 in normal tissues and tumors. Int J Mol Med. 2002;9:363–8.PubMed Katoh M. Expression of human SOX7 in normal tissues and tumors. Int J Mol Med. 2002;9:363–8.PubMed
22.
Zurück zum Zitat Li B, Ge Z, Song S, Zhang S, Yan H, Huang B, Zhang Y. Decreased expression of SOX7 is correlated with poor prognosis in lung adenocarcinoma patients. Pathol Oncol Res. 2012;18:1039–45.CrossRefPubMed Li B, Ge Z, Song S, Zhang S, Yan H, Huang B, Zhang Y. Decreased expression of SOX7 is correlated with poor prognosis in lung adenocarcinoma patients. Pathol Oncol Res. 2012;18:1039–45.CrossRefPubMed
23.
Zurück zum Zitat Cui J, Xi H, Cai A, Bian S, Wei B, Chen L. Decreased expression of Sox7 correlates with the upregulation of the Wnt/beta-catenin signaling pathway and the poor survival of gastric cancer patients. Int J Mol Med. 2014;34:197–204.PubMed Cui J, Xi H, Cai A, Bian S, Wei B, Chen L. Decreased expression of Sox7 correlates with the upregulation of the Wnt/beta-catenin signaling pathway and the poor survival of gastric cancer patients. Int J Mol Med. 2014;34:197–204.PubMed
24.
Zurück zum Zitat Lu Y, Zhang Y, Wang N, Pan Z, Gao X, Zhang F, Zhang Y, Shan H, Luo X, Bai Y, Sun L, Song W, Xu C, Wang Z, Yang B. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation. 2010;122:2378–87.CrossRefPubMed Lu Y, Zhang Y, Wang N, Pan Z, Gao X, Zhang F, Zhang Y, Shan H, Luo X, Bai Y, Sun L, Song W, Xu C, Wang Z, Yang B. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation. 2010;122:2378–87.CrossRefPubMed
25.
Zurück zum Zitat Wang XH, Qian RZ, Zhang W, Chen SF, Jin HM, Hu RM. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2009;36:181–8.CrossRefPubMed Wang XH, Qian RZ, Zhang W, Chen SF, Jin HM, Hu RM. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2009;36:181–8.CrossRefPubMed
26.
Zurück zum Zitat Zhang Q, Xiao X, Li M, Li W, Yu M, Zhang H, Wang Z, Xiang H. Acarbose reduces blood glucose by activating miR-10a-5p and miR-664 in diabetic rats. PLoS ONE. 2013;8:e79697.CrossRefPubMedPubMedCentral Zhang Q, Xiao X, Li M, Li W, Yu M, Zhang H, Wang Z, Xiang H. Acarbose reduces blood glucose by activating miR-10a-5p and miR-664 in diabetic rats. PLoS ONE. 2013;8:e79697.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Yang H, Cho ME, Li TW, Peng H, Ko KS, Mato JM, Lu SC. MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Investig. 2013;123:285–98.CrossRefPubMed Yang H, Cho ME, Li TW, Peng H, Ko KS, Mato JM, Lu SC. MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Investig. 2013;123:285–98.CrossRefPubMed
28.
Zurück zum Zitat Liu H, Yan ZQ, Li B, Yin SY, Sun Q, Kou JJ, Ye D, Ferns K, Liu HY, Liu SL. Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/beta-catenin signaling pathway. J Ovar Res. 2014;7:87.CrossRef Liu H, Yan ZQ, Li B, Yin SY, Sun Q, Kou JJ, Ye D, Ferns K, Liu HY, Liu SL. Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/beta-catenin signaling pathway. J Ovar Res. 2014;7:87.CrossRef
29.
Zurück zum Zitat Zhou X, Huang SY, Feng JX, Gao YY, Zhao L, Lu J, Huang BQ, Zhang Y. SOX7 is involved in aspirin-mediated growth inhibition of human colorectal cancer cells. World J Gastroenterol WJG. 2011;17:4922–7.CrossRefPubMed Zhou X, Huang SY, Feng JX, Gao YY, Zhao L, Lu J, Huang BQ, Zhang Y. SOX7 is involved in aspirin-mediated growth inhibition of human colorectal cancer cells. World J Gastroenterol WJG. 2011;17:4922–7.CrossRefPubMed
30.
Zurück zum Zitat Hayano T, Garg M, Yin D, Sudo M, Kawamata N, Shi S, Chien W, Ding LW, Leong G, Mori S, Xie D, Tan P, Koeffler HP. SOX7 is down-regulated in lung cancer. J Exp Clin Cancer Res. 2013;32:17.CrossRefPubMedPubMedCentral Hayano T, Garg M, Yin D, Sudo M, Kawamata N, Shi S, Chien W, Ding LW, Leong G, Mori S, Xie D, Tan P, Koeffler HP. SOX7 is down-regulated in lung cancer. J Exp Clin Cancer Res. 2013;32:17.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Chan DW, Mak CS, Leung TH, Chan KK, Ngan HY. Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer. Oncotarget. 2012;3:1546–56.CrossRefPubMedPubMedCentral Chan DW, Mak CS, Leung TH, Chan KK, Ngan HY. Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer. Oncotarget. 2012;3:1546–56.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Zhong WD, Qin GQ, Dai QS, Han ZD, Chen SM, Ling XH, Fu X, Cai C, Chen JH, Chen XB, Lin ZY, Deng YH, Wu SL, He HC, Wu CL. SOXs in human prostate cancer: implication as progression and prognosis factors. BMC Cancer. 2012;12:248.CrossRefPubMedPubMedCentral Zhong WD, Qin GQ, Dai QS, Han ZD, Chen SM, Ling XH, Fu X, Cai C, Chen JH, Chen XB, Lin ZY, Deng YH, Wu SL, He HC, Wu CL. SOXs in human prostate cancer: implication as progression and prognosis factors. BMC Cancer. 2012;12:248.CrossRefPubMedPubMedCentral
Metadaten
Titel
Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7
verfasst von
Yongzheng Bao
Bin Chen
Qiang Wu
Konghe Hu
Xinhua Xi
Wengang Zhu
Xueren Zhong
Jianting Chen
Publikationsdatum
29.10.2015
Verlag
Springer International Publishing
Erschienen in
Clinical and Experimental Medicine / Ausgabe 1/2017
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-015-0398-6

Weitere Artikel der Ausgabe 1/2017

Clinical and Experimental Medicine 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.